Abstract
We retrospectively evaluated the outcome of 94 consecutive elderly patients treated at our center for an aggressive lymphoma without a low-grade component. Median survival was 26 months and 5-year overall survival was 39% (27-50%). We then evaluated the outcome of patients refractory to or relapsing after CHOP or CHOP-like chemotherapy. Twenty patients were refractory to first-line therapy and only 1/20 is alive with active lymphoma. Eight patients achieved a partial response and only 3 maintained the partial response while the other 5 patients died. Only 2 of the 27 patients who relapsed after a first complete remission achieved a second sustained complete remission. This study suggests that conventional-dose second-line chemotherapy yields disappointing results in elderly patients with aggressive lymphomas.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Disease Progression
-
Doxorubicin / administration & dosage
-
Doxorubicin / analogs & derivatives
-
Drug Evaluation
-
Drug Resistance, Neoplasm
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Life Tables
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / mortality*
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Prognosis
-
Recurrence
-
Remission Induction
-
Retrospective Studies
-
Salvage Therapy* / statistics & numerical data
-
Survival Analysis
-
Treatment Outcome
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone
Supplementary concepts
-
CHOP protocol
-
CHOP protocol, modified